Key takeaways
- $2.125M onasemnogene one-time WAC — highest single-dose drug price at 2019 approval · Novartis
- Part B vs D intrathecal nusinersen (Part B) vs oral risdiplam (Part D) — routing creates patient OOP gap · CMS
- 5-year Zolgensma outcomes-based Medicaid agreement term — annual motor-milestone monitoring with rebates · Novartis / state Medicaid
A $2.125M one-time gene therapy, two lifetime chronic therapies, and three different benefit routings make SMA the most complex rare-disease access map in the US.
SMA is the reference case for one-time-versus-chronic payer economics. Onasemnogene abeparvovec (Zolgensma) carries a $2.125M one-time list price (the highest single-dose drug price at its 2019 approval) and prompted Novartis to negotiate the first US gene-therapy outcomes-based Medicaid contracts: a multi-year annuity structure with rebates triggered if motor milestones are not sustained over the agreement's five-year outcomes term, monitored annually. Against this sit two lifetime therapies: intrathecal nusinersen (Spinraza), with a high first-year cost and recurring maintenance dosing, and oral risdiplam (Evrysdi), priced annually and given for life.
Benefit routing splits three ways and drives access friction. Nusinersen, physician-administered by intrathecal injection, routes to Medicare Part B, with no patient out-of-pocket cost for dual-eligible beneficiaries. Risdiplam, an oral agent, routes to Part D, exposing patients to coinsurance. The oral route therefore paradoxically carries higher initial patient cost than the intrathecal route for many Medicare and Medicaid patients. Onasemnogene, a one-time infusion, is handled case-by-case, typically under an outcomes-based agreement. Over a ten-year horizon the one-time price is broadly comparable to cumulative chronic-therapy spend, which is the core economic argument payers weigh — alongside the age-under-two eligibility cliff for gene therapy.
US SMA agent payer status — 2026
| Drug (Brand / INN) | Benefit Routing | List Price (WAC) | Contracting Model | PA Criteria | Key Payer Consideration |
|---|---|---|---|---|---|
| Spinraza (nusinersen) | Medicare Part B (intrathecal, physician-administered) | ~$750K year 1; ~$375K/yr maintenance | Standard; rebates negotiated | Confirmed SMA (SMN1 deletion/mutation); any type | Recurring lifetime cost; intrathecal site-of-care |
| Zolgensma (onasemnogene abeparvovec) | Case-by-case (one-time infusion) | $2.125M one-time | Outcomes-based Medicaid annuity; 5-yr term, annual milestone rebates | Age <2; SMN1 deletion; pre-symptomatic or early symptomatic | One-time cost vs 10-yr chronic spend; age eligibility cliff |
| Evrysdi (risdiplam) | Medicare Part D (oral) | ~$340K/yr (weight-based) | Select Medicaid outcomes contracts | Confirmed SMA; all types, all ages | Part D OOP vs Part B; step-edit before gene therapy in >2y patients |
Sources: ICER 2019 SMA Final Evidence Report; Novartis, Biogen and Roche pricing disclosures; CMS Part B and Part D benefit-routing classifications; Novartis Zolgensma outcomes-based Medicaid contract announcement (2019). List prices are WAC and do not reflect confidential net rebates.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How do the one-time and chronic SMA modalities compare on total cost, and what is the ten-year cost-modelling case for gene therapy? • • $2.125M one-time vs cumulative nusinersen and risdiplam over 10 years • ICER 2019 SMA cost-effectiveness framing • Break-even horizon for one-time vs chronic therapy • Age <2 eligibility cliff and its effect on the addressable gene-therapy pool
- How are Zolgensma outcomes-based Medicaid contracts structured, and what precedent do they set? • • Annuity payment and milestone-rebate mechanics • Five-year outcomes term with annual motor-milestone monitoring • CMS best-price waiver enabling outcome-linked payment • Read-across to sickle-cell gene-therapy contracting (CGT Access Model)
- How does Part B vs Part D benefit routing affect patient OOP and payer sequencing across the three agents? • • Part B (intrathecal nusinersen) vs Part D (oral risdiplam) OOP comparison • Case-by-case handling of one-time gene therapy • Emerging step-edit and sequencing in older patients • Site-of-care and administration cost by modality
What's inside
-
1 · US Payer Landscape — SMA Coverage Architecture 4 pp
- Three distinct coverage pathways: Medicare Part B for intrathecal nusinersen, Part D for oral risdiplam, and case-by-case handling for one-time onasemnogene abeparvovec
- How prior-authorization criteria differ by drug — confirmed SMN1 deletion for nusinersen, an age-under-two eligibility cliff for gene therapy
-
2 · One-Time vs Lifetime Cost Modelling 6 pp
- The $2.125M one-time onasemnogene price against nusinersen's ~$750K first-year and ~$375K/year maintenance cost, or risdiplam's ~$340K/year
- Over a ten-year horizon the one-time gene-therapy price is broadly comparable to cumulative chronic-therapy spend, the core payer trade-off
-
3 · Zolgensma Outcomes-Based Medicaid Contracts 5 pp
- Novartis's first US gene-therapy outcomes-based Medicaid contracts: a multi-year annuity with rebates if motor milestones are not sustained
- The five-year outcomes term with annual motor-milestone monitoring that anchors the Zolgensma Medicaid agreement structure
-
4 · Part B vs Part D Routing — OOP & Access 4 pp
- Intrathecal nusinersen routes to Medicare Part B with no out-of-pocket cost for dual-eligible beneficiaries, while oral risdiplam routes to Part D with coinsurance exposure
- Why the oral route paradoxically carries higher initial patient cost than the physician-administered intrathecal route for many Medicare and Medicaid patients
-
5 · ICER 2019 Assessment & Payer PA Criteria 5 pp
- ICER's 2019 SMA Final Evidence Report set the cost-effectiveness framing payers still reference for one-time versus chronic modality comparisons
- Prior-authorization criteria across the three agents: confirmed SMN1 deletion/mutation for nusinersen, age-under-two for onasemnogene, all types/ages for risdiplam
-
6 · Sequencing, Step-Edit & Pipeline Access 3 pp
- Emerging step-edit requirements before gene therapy in symptomatic patients over age two, sequencing chronic therapy first
- How the Zolgensma Medicaid annuity model reads across to CMS's CGT Access Model precedent for sickle-cell gene-therapy contracting
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Spinal Muscular Atrophy Payer & HTA is built for market access, HEOR, and pricing teams navigating one-time gene-therapy economics, outcomes-based contracting, and Part B/D routing in the US SMA market. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, payer focus (cost modelling, outcomes contracts, PA criteria), and commercial question.
- 2. Scoping callAXLRx analyst confirms payer scope, cost-model assumptions, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
SMA payer and HTA analysis is built from ICER evidence reports, CMS benefit-routing and Medicaid outcomes-contracting documentation, manufacturer pricing disclosures, and live payer formulary and PA policy documents.
Key sources: ICER 2019 SMA Final Evidence Report; Novartis Zolgensma outcomes-based Medicaid contract announcement (2019); CMS Part B and Part D benefit-design and drug-payment classifications; CMS CMMI outcomes-based contracting framework; and current commercial and Medicaid PA coverage policies.
- Zolgensma one-time WAC verified against Novartis 2019 pricing disclosure
- Part B vs Part D benefit routing verified against CMS drug-classification criteria
- Zolgensma outcomes-based Medicaid contract structure verified against Novartis 2019 announcement and CMS CMMI framework
- ICER SMA cost-effectiveness framing verified against ICER 2019 SMA Final Evidence Report
Frequently asked questions
Access Why is SMA the most complex payer landscape in rare disease?
Three approved modalities route through three different benefits. Onasemnogene abeparvovec (Zolgensma) is a one-time $2.125M infusion handled case-by-case under outcomes-based contracts; intrathecal nusinersen (Spinraza) routes to Medicare Part B; and oral risdiplam (Evrysdi) routes to Part D. Payers must weigh a one-time price against lifetime chronic-therapy cost, with age under two and SMN2 copy number gating gene-therapy eligibility.
Pricing How do Zolgensma outcomes-based contracts work?
Novartis negotiated the first US gene-therapy outcomes-based Medicaid contracts for Zolgensma: a multi-year annuity payment structure with milestone-triggered rebates if a child does not sustain motor-function milestones over a five-year outcomes term, monitored annually. CMS granted a best-price rebate waiver to enable the outcome-linked payments, and the model has since become a template for sickle-cell gene-therapy contracting under the CMS Cell and Gene Therapy (CGT) Access Model.
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.